LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Listă Acțiuni・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Închisă

SectorSănătate

181.15 -2.43

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

180.11

Maxim

185.16

Indicatori cheie
By Trading Economics
Venit	262M -15M
Vânzări	1.6M 996M
EPS	-0.3
Marjă de profit	-1.486
Angajați	18,300
EBITDA	-11M 187M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+12.17% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	267M 8.8B
Deschiderea anterioară	183.58
Închiderea anterioară	181.15

Sentimentul știrilor

By Acuity

50%

155 / 344 Clasament în Healthcare

Charles River Laboratories International Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 iun. 2026, 19:20 UTC

Principalele dinamici ale pieței

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 iun. 2026, 21:27 UTC

Câștiguri

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 iun. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 iun. 2026, 20:20 UTC

Achiziții, Fuziuni, Preluări

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 iun. 2026, 20:19 UTC

Achiziții, Fuziuni, Preluări

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 iun. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 iun. 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 iun. 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 iun. 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 iun. 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 iun. 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 iun. 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 iun. 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 iun. 2026, 18:33 UTC

Achiziții, Fuziuni, Preluări

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 iun. 2026, 17:50 UTC

Câștiguri

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 iun. 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 iun. 2026, 16:48 UTC

Achiziții, Fuziuni, Preluări

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 iun. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 iun. 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 iun. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 iun. 2026, 15:44 UTC

Achiziții, Fuziuni, Preluări

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 iun. 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 iun. 2026, 15:25 UTC

Câștiguri

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 iun. 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 iun. 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 iun. 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 iun. 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 iun. 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparație

Modificare preț

Charles River Laboratories International Inc Așteptări

Obiectiv de preț

By TipRanks

12.17% sus

Prognoză pe 12 luni

Medie 208.4 USD 12.17%

Maxim 235 USD

Minim 160 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCharles River Laboratories International Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 11 analiști care au acordat evaluări ale acțiunilor Charles River Laboratories International Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

155 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.